Syncona Share Chat (SYNC)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Syncona	LSE:SYNC	London	Ordinary Share	GG00B8P59C08	ORD NPV

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.50p	+0.22%	223.50p	224.00p	225.00p	225.00p	224.00p	225.00p	269,053	16:35:28

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Equity Investment Instruments	28.7	5.1	0.8	286.5	1,474.99

Syncona Share Discussion Threads

Showing 18326 to 18350 of 18350 messages

Chat Pages: 734 733 732 731 730 729 728 727 726 725 724 723 Older

Date	Subject	Author	Discuss
19/6/2018 08:26	Plenty going on here. Two new investments plus today’s increased investment in Freeline. And a strategic theme in gene therapy.	brexitplus	Read Full Thread Reply
15/6/2018 03:37	The results presentation: htTps://www.synconaltd.com/wp-content/uploads/2017/07/Syncona-Full-Year-Results-Presentation-14062018.pdf And the results themselves: httPs://www.synconaltd.com/wp-content/uploads/2017/07/Syncona-Ltd-Full-Year-Results-2018.pdf	rambutan2	Read Full Thread Reply
14/6/2018 12:06	Indeed all is looking good and whilst its a little out of the limelight the price remains a bargain in my opinion. I added today and plan to add more should there be any dips.	audigger	Read Full Thread Reply
14/6/2018 11:11	Nitestar awarded Rmat which is the road to “accelerated approval”	ltinvestor	Read Full Thread Reply
14/6/2018 07:36	Totally agree. The approach and choice of investments is excellent. Very professional.	brexitplus	Read Full Thread Reply
14/6/2018 07:24	I am quite amazed by the lack of Pi interest in Syncona.Todays results give a snapshot of the potential here with regard to their investments in the field of gene therapy....	ltinvestor	Read Full Thread Reply
13/6/2018 08:01	Autolus to ipo on Nasdaq 22/6	ltinvestor	Read Full Thread Reply
10/6/2018 12:59	Autolus has a unique advantage over other car T therapies in that their car T has a built in “off switch”.This will help reduce adverse reactions found with other T cell therapies.Autolus excites me more than their other subsidiary holdings and in time has the potential to be worth billions...	ltinvestor	Read Full Thread Reply
08/6/2018 12:25	Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus̶1;) has filed an amended registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering in the United States of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share. The registration statement discloses an indicative pricing range for the proposed offering of U.S.$15.00 – U.S.$17.00 per ADS. This would represent an increase in value of Syncona’s current shareholding in Autolus (compared to the 30 April 2018 sterling holding value) of £49.5 – £67.7 million[1] (7.4p-10.2p per Syncona share). The proposed maximum aggregate offering amount specified in the filing is U.S.$125.0 million, which assumes that the offering price is at the midpoint of the indicative pricing range and does not include the underwriters’ option to purchase additional ADSs.	alan@bj	Read Full Thread Reply
31/5/2018 17:47	Indeed it is moving along nicely. I like the business models which allows exposure to a portfolio of life science start-ups which would otherwise be unavailable for investment. Definitely less risky than buying in to early stage companies reliant on a single technology.	audigger	Read Full Thread Reply
25/5/2018 15:54	.....and today another high.Where is everybody?	ltinvestor	Read Full Thread Reply
24/5/2018 09:22	Today the share price has reached an all time high and no wonder with its holdings.Under the radar at the moment with Pi’s but not institutions.	ltinvestor	Read Full Thread Reply
15/5/2018 14:20	hxxps://www.businesswire.com/news/home/20180514005319/en/Blue-Earth-Diagnostics-Announces-Presentation-Fluciclovine-18F Apparently a poster on the results of the LOCATE clinical trial (NCT02680041) will be presented in the next week. 220 patients for: Primary Outcome Measures : The fraction of patients for whom 18F-fluciclovine PET/CT alters patient planned treatment through detection of disease. [ Time Frame: 2-22 days post PET CT ] The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT Secondary Outcome Measures : The fraction of patients for whom 18F-fluciclovine PET/CT alters patient actual treatment [ Time Frame: 6 months ] The rate of detection of any disease site by 18F-fluciclovine PET/CT in the study population [ Time Frame: 1 week ] The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT The rate of detection of 1) local and pelvic disease and 2) distant metastases with 18F-fluciclovine PET/CT in the study population [ Time Frame: 1 week ] The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally	luxaeterna1	Read Full Thread Reply
15/5/2018 11:56	I was very fortunate and bought in during the first few weeks of the fund @ about £1.30. Thankfully it was a modest purchase, offsetting some fairly terrible other stocks in my portfolio!	luxaeterna1	Read Full Thread Reply
13/5/2018 10:48	I bought a large number at £1.65 so very happy.	ltinvestor	Read Full Thread Reply
13/5/2018 09:42	I am invested here. I bought in at 159p.	alan@bj	Read Full Thread Reply
13/5/2018 08:14	Alan.Autolus have built a “switch” in the Car T cell so they have the ability to can turn off the treatment at any time.Syncona is under the PI radar at the moment but not the institutions.This is one investment that you lock in the bottom drawer and watch it grow year on year.Dyor and do not take this as investment advice...	ltinvestor	Read Full Thread Reply
12/5/2018 14:37	Thank you Iti.	alan@bj	Read Full Thread Reply
12/5/2018 13:19	It is on one of the forms and apparently is an approximation.If you google Autolus you will find a couple of articles re the listing etc	ltinvestor	Read Full Thread Reply
11/5/2018 17:24	Where did you find that information, Iti? Is Syncona participating in the fund raising?	alan@bj	Read Full Thread Reply
11/5/2018 16:42	Raising $100m prior to listing..	ltinvestor	Read Full Thread Reply
10/5/2018 20:26	Therein lies opportunity :-) DL	davidlloyd	Read Full Thread Reply
08/5/2018 08:20	No price movement on announcement as no details.	brexitplus	Read Full Thread Reply
08/5/2018 07:42	Syncona have a 38.6% share of Autolus and the Nasdaq listing should show a significant uplift in Synconas nav.	ltinvestor	Read Full Thread Reply
08/5/2018 07:12	Autolus files for proposed initial public offering in the United States 8 May 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus̶1;) has filed a registration statement on Form F-1 (“Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share. All ADSs to be sold in the proposed IPO will be offered by Autolus. Autolus intends to apply to list its ADSs on the Nasdaq Global Market under the ticker symbol “AUTL”. The number of ADSs to be sold and the pricing terms for the proposed IPO have not yet been determined.	brexitplus	Read Full Thread Reply

Chat Pages: 734 733 732 731 730 729 728 727 726 725 724 723 Older

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.